Belite Bio, Inc (BLTE)
NASDAQ: BLTE · Real-Time Price · USD
179.12
+5.82 (3.36%)
At close: Mar 9, 2026, 4:00 PM EDT
182.00
+2.88 (1.61%)
After-hours: Mar 9, 2026, 7:48 PM EDT
Belite Bio Employees
Belite Bio had 25 employees as of December 31, 2024. The number of employees increased by 5 or 25.00% compared to the previous year.
Employees
25
Change (1Y)
5
Growth (1Y)
25.00%
Revenue / Employee
n/a
Profits / Employee
-$3,104,440
Market Cap
7.05B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 25 | 5 | 25.00% |
| Dec 31, 2023 | 20 | 4 | 25.00% |
| Dec 31, 2022 | 16 | 4 | 33.33% |
| Dec 31, 2021 | 12 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Axsome Therapeutics | 925 |
| Arrowhead Pharmaceuticals | 711 |
| Cytokinetics | 673 |
| Halozyme Therapeutics | 423 |
| Rhythm Pharmaceuticals | 414 |
| Krystal Biotech | 295 |
| Cogent Biosciences | 258 |
| Kymera Therapeutics | 238 |
BLTE News
- 6 days ago - Belite Bio, Inc (BLTE) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 7 days ago - Belite Bio Reports Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 3 months ago - Belite Bio Announces Pricing of $350.0 Million Underwritten Public Offering of American Depositary Shares - GlobeNewsWire
- 3 months ago - Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares - GlobeNewsWire
- 3 months ago - Belite Bio, Inc (BLTE) Discusses Positive Topline Results from Phase III DRAGON Trial of Tinlarebant in Stargardt Disease Transcript - Seeking Alpha
- 3 months ago - Belite Bio Scores First Successful Phase 3 Trial For Rare Vision-Loss Disease - Benzinga
- 3 months ago - Belite Bio's drug for genetic eye disease meets main goal in late-stage trial - Reuters
- 3 months ago - New Hope for People Living with a Disease Once Deemed Untreatable: Belite Bio Announces Positive Topline Results from the Pivotal Global, Phase 3 DRAGON Trial of Tinlarebant in Adolescents with Stargardt Disease - GlobeNewsWire